162 related articles for article (PubMed ID: 27565356)
21. Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.
Chugh S; Gnanapragassam VS; Jain M; Rachagani S; Ponnusamy MP; Batra SK
Biochim Biophys Acta; 2015 Dec; 1856(2):211-25. PubMed ID: 26318196
[TBL] [Abstract][Full Text] [Related]
22. Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis.
Rodrigues JG; Balmaña M; Macedo JA; Poças J; Fernandes Â; de-Freitas-Junior JCM; Pinho SS; Gomes J; Magalhães A; Gomes C; Mereiter S; Reis CA
Cell Immunol; 2018 Nov; 333():46-57. PubMed ID: 29576316
[TBL] [Abstract][Full Text] [Related]
23. Protein glycosylation in gastric and colorectal cancers: Toward cancer detection and targeted therapeutics.
Ferreira JA; Magalhães A; Gomes J; Peixoto A; Gaiteiro C; Fernandes E; Santos LL; Reis CA
Cancer Lett; 2017 Feb; 387():32-45. PubMed ID: 26828132
[TBL] [Abstract][Full Text] [Related]
24. Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.
Boligan KF; Mesa C; Fernandez LE; von Gunten S
Cell Mol Life Sci; 2015 Apr; 72(7):1231-48. PubMed ID: 25487607
[TBL] [Abstract][Full Text] [Related]
25. Glycans in cancer and inflammation--potential for therapeutics and diagnostics.
Dube DH; Bertozzi CR
Nat Rev Drug Discov; 2005 Jun; 4(6):477-88. PubMed ID: 15931257
[TBL] [Abstract][Full Text] [Related]
26. Branched N-glycans regulate the biological functions of integrins and cadherins.
Zhao Y; Sato Y; Isaji T; Fukuda T; Matsumoto A; Miyoshi E; Gu J; Taniguchi N
FEBS J; 2008 May; 275(9):1939-48. PubMed ID: 18384383
[TBL] [Abstract][Full Text] [Related]
27. The role of N-glycans in colorectal cancer progression: potential biomarkers and therapeutic applications.
de Freitas Junior JC; Morgado-Díaz JA
Oncotarget; 2016 Apr; 7(15):19395-413. PubMed ID: 26539643
[TBL] [Abstract][Full Text] [Related]
28. Role of protein glycosylation in cancer metastasis.
Oliveira-Ferrer L; Legler K; Milde-Langosch K
Semin Cancer Biol; 2017 Jun; 44():141-152. PubMed ID: 28315783
[TBL] [Abstract][Full Text] [Related]
29. Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins.
Takahashi M; Kuroki Y; Ohtsubo K; Taniguchi N
Carbohydr Res; 2009 Aug; 344(12):1387-90. PubMed ID: 19508951
[TBL] [Abstract][Full Text] [Related]
30. Key regulators of galectin-glycan interactions.
Kamili NA; Arthur CM; Gerner-Smidt C; Tafesse E; Blenda A; Dias-Baruffi M; Stowell SR
Proteomics; 2016 Dec; 16(24):3111-3125. PubMed ID: 27582340
[TBL] [Abstract][Full Text] [Related]
31. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
32. Altered Glycosylation in Progression and Management of Bladder Cancer.
Wilczak M; Surman M; Przybyło M
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110670
[TBL] [Abstract][Full Text] [Related]
33. I-branched carbohydrates as emerging effectors of malignant progression.
Dimitroff CJ
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):13729-13737. PubMed ID: 31213534
[TBL] [Abstract][Full Text] [Related]
34. Aberrant protein glycosylation in cancer: implications in targeted therapy.
Rodrigues JG; Duarte HO; Reis CA; Gomes J
Biochem Soc Trans; 2021 Apr; 49(2):843-854. PubMed ID: 33704376
[TBL] [Abstract][Full Text] [Related]
35. Clinical aspects of altered glycosylation of glycoproteins in cancer.
Orntoft TF; Vestergaard EM
Electrophoresis; 1999 Feb; 20(2):362-71. PubMed ID: 10197444
[TBL] [Abstract][Full Text] [Related]
36. Cancer glycan epitopes: biosynthesis, structure and function.
Pearce OMT
Glycobiology; 2018 Sep; 28(9):670-696. PubMed ID: 29546349
[TBL] [Abstract][Full Text] [Related]
37. Functional impact of tumor-specific N-linked glycan changes in breast and ovarian cancers.
Guo H; Abbott KL
Adv Cancer Res; 2015; 126():281-303. PubMed ID: 25727151
[TBL] [Abstract][Full Text] [Related]
38. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.
Tsuiji H; Takasaki S; Sakamoto M; Irimura T; Hirohashi S
Glycobiology; 2003 Jul; 13(7):521-7. PubMed ID: 12672699
[TBL] [Abstract][Full Text] [Related]
39. Predominant Expression of Hybrid N-Glycans Has Distinct Cellular Roles Relative to Complex and Oligomannose N-Glycans.
Hall MK; Weidner DA; Zhu Y; Dayal S; Whitman AA; Schwalbe RA
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304954
[TBL] [Abstract][Full Text] [Related]
40. Glycosylation and metastases.
Josic D; Martinovic T; Pavelic K
Electrophoresis; 2019 Jan; 40(1):140-150. PubMed ID: 30246896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
